share_log

Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial

Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial

禮來公司宣佈了SURMOUNt-5第30億期隨機開放臨床試驗的頭條結果
Benzinga ·  12/04 11:46

Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial

禮來公司公佈了SURMOUNt-5三期開放標籤隨機臨床試驗的頂線結果

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論